937 related articles for article (PubMed ID: 33579788)
1. Maintenance therapy with infliximab or vedolizumab in IBD is not associated with increased SARS-CoV-2 seroprevalence: UK experience in the 2020 pandemic.
McGregor CG; Adams A; Sadler R; Arancibia-Cárcamo CV; Palmer R; Ambrose T; Brain O; Walsh A; Klenerman P; Travis SP; Croft NM; Lindsay JO; Satsangi J
Gut; 2021 Dec; 70(12):2398-2400. PubMed ID: 33579788
[No Abstract] [Full Text] [Related]
2. Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab.
Kennedy NA; Goodhand JR; Bewshea C; Nice R; Chee D; Lin S; Chanchlani N; Butterworth J; Cooney R; Croft NM; Hart AL; Irving PM; Kok KB; Lamb CA; Limdi JK; Macdonald J; McGovern DP; Mehta SJ; Murray CD; Patel KV; Pollok RC; Raine T; Russell RK; Selinger CP; Smith PJ; Bowden J; McDonald TJ; Lees CW; Sebastian S; Powell N; Ahmad T;
Gut; 2021 May; 70(5):865-875. PubMed ID: 33753421
[TBL] [Abstract][Full Text] [Related]
3. Cytokine signature in convalescent SARS-CoV-2 patients with inflammatory bowel disease receiving vedolizumab.
Dallari S; Martinez Pazos V; Munoz Eusse J; Wellens J; Thompson C; Colombel JF; Satsangi J; Cadwell K; Wong SY;
Sci Rep; 2024 Jan; 14(1):186. PubMed ID: 38168138
[TBL] [Abstract][Full Text] [Related]
4. Combination therapy of infliximab and thiopurines, but not monotherapy with infliximab or vedolizumab, is associated with attenuated IgA and neutralisation responses to SARS-CoV-2 in inflammatory bowel disease.
Wellens J; Edmans M; Obolski U; McGregor CG; Simmonds P; Turner M; Jarvis L; Skelly D; Dunachie S; Barnes E; Eyre DW; Colombel JF; Wong SY; Klenerman P; Lindsay JO; Satsangi J; Thompson CP
Gut; 2022 Sep; 71(9):1919-1922. PubMed ID: 34911744
[No Abstract] [Full Text] [Related]
5. A Seroprevalence Study of Anti-SARS-CoV-2 Antibodies in Patients with Inflammatory Bowel Disease during the Second Wave of the COVID-19 Pandemic in Italy.
Di Ruscio M; Lunardi G; Buonfrate D; Gobbi F; Bertoli G; Piccoli D; Conti A; Geccherle A; Variola A
Medicina (Kaunas); 2021 Oct; 57(10):. PubMed ID: 34684085
[No Abstract] [Full Text] [Related]
6. Adalimumab and Infliximab Impair SARS-CoV-2 Antibody Responses: Results from a Therapeutic Drug Monitoring Study in 11 422 Biologic-Treated Patients.
Chanchlani N; Lin S; Chee D; Hamilton B; Nice R; Arkir Z; Bewshea C; Cipriano B; Derikx LAAP; Dunlop A; Greathead L; Griffiths RL; Ibraheim H; Kelleher P; Kok KB; Lees CW; MacDonald J; Sebastian S; Smith PJ; McDonald TJ; Irving PM; Powell N; Kennedy NA; Goodhand JR; Ahmad T
J Crohns Colitis; 2022 Mar; 16(3):389-397. PubMed ID: 34473254
[TBL] [Abstract][Full Text] [Related]
7. The risk of COVID-19 in IBD patients is increased by urban living and is not influenced by disease activity or intravenous biologics.
Lelong M; Josien R; Coste-Burel M; Rimbert M; Bressollette-Bodin C; Nancey S; Bouguen G; Allez M; Serrero M; Caillo L; Rouillon C; Blanc P; Laharie D; Olivier R; Peyrin-Biroulet L; Dib N; De Maissin A; Montuclard C; Trang-Poisson C; Vavasseur F; Gallot G; Berthome M; Braudeau C; Chevreuil J; Bourreille A; Le Berre C
Front Immunol; 2023; 14():1243898. PubMed ID: 37701431
[TBL] [Abstract][Full Text] [Related]
8. Inflammatory bowel disease and SARS-CoV-2 pandemic: current knowledge and recommendations.
Bekic D; Belosic Halle Z
Scand J Gastroenterol; 2021 Jun; 56(6):656-660. PubMed ID: 33765405
[TBL] [Abstract][Full Text] [Related]
9. Letter: risk of severe COVID-19 outcomes associated with inflammatory bowel disease medications-reassuring insights from the United Kingdom PREPARE-IBD multicentre cohort study.
Lamb CA; Sebastian S; Kent AJ; Segal JP; Gonzalez HA; Brookes MJ; Mehta SJ; Subramanian S; Bhala N; Hicks LC; Conley TE; Patel KV; Walker GJ; Kennedy NA;
Aliment Pharmacol Ther; 2021 Jun; 53(11):1236-1240. PubMed ID: 33961708
[TBL] [Abstract][Full Text] [Related]
10. Comparative Analysis of the 3-Year Persistence Rate with Second-Line Vedolizumab and Tumor Necrosis Factor-α Inhibitors in Patients with Inflammatory Bowel Disease Followed in Gastroenterology Practices in Germany.
Helwig U; Braegger F; Kostev K; Schmidt C
Dig Dis; 2020; 38(6):466-473. PubMed ID: 32045927
[TBL] [Abstract][Full Text] [Related]
11. Managing an IBD Infusion Unit During the COVID-19 Pandemic: Service Modifications and the Patient Perspective.
Clough JN; Hill KL; Duff A; Sharma E; Ray S; Mawdsley JE; Anderson S; Irving PM; Samaan MA
Inflamm Bowel Dis; 2020 Sep; 26(10):e125-e126. PubMed ID: 32592475
[No Abstract] [Full Text] [Related]
12. Editorial: IBD medications during the COVID-19 pandemic-are they safe to use?
Fan D; Gearry RB
Aliment Pharmacol Ther; 2021 Jul; 54(2):208-209. PubMed ID: 34170535
[TBL] [Abstract][Full Text] [Related]
13. Management of IBD Patients Who Are Unwilling or Unable to Receive Infusion Therapy During the COVID-19 Pandemic.
Horrigan JM; Siegel CA; Tadros M
Inflamm Bowel Dis; 2020 Oct; 26(11):e137. PubMed ID: 32737970
[No Abstract] [Full Text] [Related]
14. Preserved SARS-CoV-2 Vaccine Cell-Mediated Immunogenicity in Patients With Inflammatory Bowel Disease on Immune-Modulating Therapies.
Boland BS; Goodwin B; Zhang Z; Bloom N; Kato Y; Neill J; Le H; Tysl T; Collins AE; Dulai PS; Singh S; Nguyen NH; Grifoni A; Sette A; Weiskopf D; Chang JT; Dan JM
Clin Transl Gastroenterol; 2022 Apr; 13(4):e00484. PubMed ID: 35347100
[TBL] [Abstract][Full Text] [Related]
15. Impact of COVID-19 on diagnosis and management of paediatric inflammatory bowel disease during lockdown: a UK nationwide study.
Ashton JJ; Kammermeier J; Spray C; Russell RK; Hansen R; Howarth LJ; Torrente F; Deb P; Renji E; Muhammed R; Paul T; Kiparissi F; Epstein J; Lawson M; Hope B; Zamvar V; Narula P; Kadir A; Devadason D; Bhavsar H; Beattie RM
Arch Dis Child; 2020 Dec; 105(12):1186-1191. PubMed ID: 32732316
[TBL] [Abstract][Full Text] [Related]
16. COVID-19 and IBD drugs: should we change anything at the moment?
Lees CW; Irving PM; Beaugerie L
Gut; 2021 Apr; 70(4):632-634. PubMed ID: 33214164
[No Abstract] [Full Text] [Related]
17. Infusion administration billing for vedolizumab and infliximab in inflammatory bowel disease.
Null K; Kumar V; Lissoos T; Luo M
J Med Econ; 2018 Nov; 21(11):1102-1109. PubMed ID: 30101633
[TBL] [Abstract][Full Text] [Related]
18. Patient-led Remote IntraCapillary pharmacoKinetic Sampling (fingerPRICKS) for Therapeutic Drug Monitoring in patients with Inflammatory Bowel Disease.
Chee D; Nice R; Hamilton B; Jones E; Hawkins S; Redstone C; Cairnes V; Pohl K; Chanchlani N; Lin S; Kennedy NA; Ahmad T; Goodhand JR; McDonald TJ
J Crohns Colitis; 2022 Feb; 16(2):190-198. PubMed ID: 34289028
[TBL] [Abstract][Full Text] [Related]
19. The Adherence to Infusible Biologic Therapies in Inflammatory Bowel Disease Patients during the COVID-19 Pandemic: Is It Really a Problem?
Barberio B; Zingone F; Bertani L; Savarino E
Gastroenterology; 2021 Apr; 160(5):1903-1904. PubMed ID: 32687929
[No Abstract] [Full Text] [Related]
20. Impact of COVID-19 on inflammatory bowel disease practice and perspectives for the future.
Viganò C; Mulinacci G; Palermo A; Barisani D; Pirola L; Fichera M; Invernizzi P; Massironi S
World J Gastroenterol; 2021 Sep; 27(33):5520-5535. PubMed ID: 34588749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
